H 1121 – MassachusettsStatus: In Process
Year Introduced: 2021
Relative to maximum allowable costs lists utilized by payers and pharmaceutical benefit managers to identify the maximum amount health plans will pay for certain prescription drugs. Notwithstanding any general or special law to the contrary, there shall be a special commission established to investigate the use of maximum allowable costs lists, utilized by payers and pharmaceutical benefit managers to identify the maximum amount that a plan will pay for various prescription drugs. The commission’s review shall include, but not be limited to, current practices surrounding the determination and use of maximum allowable costs lists and their financial implications; industry-wide standardization for the development and use of maximum allowable costs lists; and transparency into the processes of developing and utilizing maximum allowable costs lists.
The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.